Acurx Pharmaceuticals, Inc. (ACXP) News

Acurx Pharmaceuticals, Inc. (ACXP): $3.46

0.11 (+3.28%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ACXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

Filter ACXP News Items

ACXP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ACXP News Highlights

  • For ACXP, its 30 day story count is now at 4.
  • Over the past 17 days, the trend for ACXP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest ACXP News From Around the Web

Below are the latest news stories about ACURX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACXP as an investment opportunity.

New to The Street Signs Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support

New to The Street Sign Acurx Pharmaceuticals, Inc. to Additional Six-Month Media Contract with Iconic Billboard Ads and Commercial Support FMW Media's business TV show, New to The Street, announces signing Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ($ACXP) ("Acurx") to an additional six-month media contract for filming and broadcasting tailored interviews, commercials, and digital billboard ads - https://www.acurxpharma.com/ & https://www.newtothestreet.com/ NEW YORK, March 23, 2023 (GLOBE NEWSW

Yahoo | March 23, 2023

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Greetings and welcome to the Acurx Pharmaceutical Fourth Quarter and Full Year 2022 Financial Results and Business Update. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Robert Shawah, Chief Financial Officer. Thank you, […]

Yahoo | March 18, 2023

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the fourth quarter and full year ended December 31, 2022.

Yahoo | March 16, 2023

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its fourth quarter 2022 and fiscal year end 2022 financial results on Thursday, March 16, 2022, at 8:00 am ET before the U.S. financial markets open.

Yahoo | March 6, 2023

Acurx is Setting a High Bar for New Treatments in C. diff

A New Gold Standard for C. diff Therapy Could be in the Offing;

Yahoo | February 14, 2023

CEO Spotlight: Acurx Pharmaceuticals CEO Confident His Phase 2b Ibezapolstat Drug Candidate Can Earn Front-Line Designation to Treat C. difficile

Acurx Pharmaceuticals CEO David Luci tells Soulstring Media Group why he thinks his company and lead drug candidate, Ibezapolstat, can be a front-line treatment against C. difficile New York, New York--(Newsfile Corp. - February 7, 2023) - Soulstring Media Group, Llc., a market research, aggregator, and digital media production and management company specializing in creating and syndicating content from publicly traded and private companies, announced today that it had published an in-depth inte

Yahoo | February 7, 2023

Presenting on the Emerging Growth Conference on January 25 Register Now

MIAMI, Jan. 24, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 48th Emerging Growth Conference on January 25, 2022. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting companies

Yahoo | January 24, 2023

Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. diff

C. diff is a life-threatening bacterial infection that causes diarrhea and colitis, which is the inflammation of the colon. Approximately 600,000 are diagnosed with C. diff each year in the United ...

Yahoo | January 19, 2023

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, is pleased to announce that it has been invited to present at the Emerging Growth Conference on January 25, 2023. This live, interactive online event will provide existing stockholders and the investment community with the opportunity to interact with the Company's President & Chief Executive Officer,

Yahoo | January 16, 2023

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2022 Earnings Call Transcript November 14, 2022 Acurx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.32 EPS, expectations were $-0.28. Operator: Greetings. Welcome to Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022. At this time, all participants are in a listen-only mode. […]

Yahoo | December 29, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5889 seconds.